NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) has recently received a non-binding expression of interest (EOI) from The Column Group, LP and its affiliated investment funds and individuals. This EOI outlines their intention to explore the possibility of acquiring all outstanding shares of the company, except those already owned by them, in a transaction that would take the company private. In response, the company?s Board of Directors has taken action by forming a special committee.

This committee consists of directors who are impartial and independent, and their primary task is to carefully evaluate the EOI, along with other strategic alternatives available to the company. These alternatives include the option of remaining a publicly-traded entity. To ensure a thorough and unbiased evaluation, the special committee has engaged Hogan Lovells US LLP as its independent legal advisor.

Additionally, they plan to enlist the expertise of an independent financial advisor to aid in the evaluation process.